




RealRate

PHARMACEUTICAL 2018

Lixte Biotechnology Holdings INC
Rank 237 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Lixte Biotechnology Holdings INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is 181%, being 71% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	1,368
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	373
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	1.4
Other Revenues	0
Property and Equipment	0
Research and Development	467
Selling, General and Administrative Expense	1,343

Output Variable	Value in 1000 USD
Assets	1,368
Liabilities	373
Expenses	1,810
Revenues	0
Stockholders Equity	995
Net Income	-1,808
Comprehensive Net Income	-1,808
BaseVar	1,776
ECR before LimitedLiability	41%
Economic Capital Ratio	181%